Findings

What do systematic reviews say?

9 questions · 9 findings · 7 reviews

No studies found 1 · 11.1%GRADE not reported 1 · 11.1%Very low 5 · 55.6%Low 2 · 22.2%Moderate 0 · 0%High 0 · 0%

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Adverse events · people with postpolio syndrome

1 finding from 1 review

Treatment for postpolio syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
GRADE not reported

Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders

It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Modafinil for people with schizophrenia or related disorders 2019 · Cochrane Headline outcomes only
RR 0.84 [0.06, 12.42]
1 study · 35 participants
Very low

Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia

Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).

1 finding from 1 review

Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes only
OR 1.68 [0.28, 9.94]
Studies not reported
Low

Adverse events ( · people with a primary brain tumour

It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
RR 2.79 [0.59, 13.16]
1 study · 37 participants
Very low

Adverse events (grade ≥ 3) · people with a primary brain tumour

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 328 participants
Low

Adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Serious adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low